Efficacy and safety of adalimumab in ankylosing spondylitis.

Even patients with total spinal ankylosis achieved ASAS 20 responses at week 12 (3/6 versus 0/5), although, due to low patient numbers, the difference did not reach statistical significance.

also in 111,027 other papers